{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:00:01Z","timestamp":1793296801577,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jval.2022.07.009","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:41:28Z","timestamp":1660351288000},"page":"185-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies"],"prefix":"10.1016","volume":"26","author":[{"given":"Stephen","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Borget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Husereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Karnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Medin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth F.P.","family":"Peterse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven L.","family":"Klijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth J.M.","family":"Verburg-Baltussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Borrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2022.07.009_bib4","author":"Latimer"},{"issue":"9","key":"10.1016\/j.jval.2022.07.009_bib5","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s40273-019-00806-4","article-title":"Estimating lifetime benefits associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations","volume":"37","author":"Ouwens","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2022.07.009_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12874-020-00997-x","article-title":"Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection","volume":"20","author":"Bullement","year":"2020","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"10.1016\/j.jval.2022.07.009_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0272989X20978958","article-title":"Extrapolation of survival curves using standard parametric models and flexible parametric spline models: comparisons in large registry cohorts with advanced cancer","volume":"41","author":"Gray","year":"2021","journal-title":"Med Decis Making"},{"issue":"3","key":"10.1016\/j.jval.2022.07.009_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40273-020-00989-1","article-title":"What did time tell us? A comparison and retrospective validation of different survival extrapolation methods for immuno-oncologic therapy in advanced or metastatic renal cell carcinoma","volume":"39","author":"Klijn","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2022.07.009_bib9","author":"Rutherford"},{"issue":"2","key":"10.1016\/j.jval.2022.07.009_bib10","article-title":"Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective","volume":"8","author":"Quinn","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jval.2022.07.009_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2288-11-96","article-title":"Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models","volume":"11","author":"Andersson","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jval.2022.07.009_bib12","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"Robins-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2022.07.009_bib13","author":"Higgins"},{"issue":"24","key":"10.1016\/j.jval.2022.07.009_bib14","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1002\/sim.9114","article-title":"Borrowing from supplemental sources to estimate causal effects from a primary data source","volume":"40","author":"Boatman","year":"2021","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.jval.2022.07.009_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0272989X16670604","article-title":"Extrapolation of survival curves from cancer trials using external information","volume":"37","author":"Guyot","year":"2017","journal-title":"Med Decis Making"},{"issue":"9","key":"10.1016\/j.jval.2022.07.009_bib16","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jval.2019.03.017","article-title":"Extrapolating survival data using historical trial-based a priori distributions","volume":"22","author":"Soikkeli","year":"2019","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2022.07.009_bib17","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/sim.8465","article-title":"Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data","volume":"39","author":"Papanikos","year":"2020","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.jval.2022.07.009_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12874-021-01292-z","article-title":"Classifying information-sharing methods","volume":"21","author":"Nikolaidis","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"10.1016\/j.jval.2022.07.009_bib19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/0272989X16639900","article-title":"Extrapolating survival from randomized trials using external data: a review of methods","volume":"37","author":"Jackson","year":"2017","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2022.07.009_bib20","series-title":"Elicitation: The Science and Art of Structuring Judgement","first-page":"61","article-title":"SHELF: the Sheffield elicitation framework","author":"Gosling","year":"2018"},{"issue":"37","key":"10.1016\/j.jval.2022.07.009_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta25370","article-title":"Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study","volume":"25","author":"Bojke","year":"2021","journal-title":"Health Technol Assess"},{"issue":"3","key":"10.1016\/j.jval.2022.07.009_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40273-019-00859-5","article-title":"Potential bias associated with modeling the effectiveness of healthcare interventions in reducing mortality using an overall hazard ratio","volume":"38","author":"Alarid-Escudero","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2022.07.009_bib23","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.jval.2022.07.009_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12874-016-0110-x","article-title":"Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated","volume":"16","author":"Royston","year":"2016","journal-title":"BMC Med Res Methodol"},{"issue":"10022","key":"10.1016\/j.jval.2022.07.009_bib25","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial [published correction appears in Lancet. 2016;387(10022):944]","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jval.2022.07.009_bib26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12916-016-0743-y","article-title":"Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation [published correction appears in BMC Med. 2017;15(1):31]","volume":"14","author":"Kearns","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.jval.2022.07.009_bib27","author":"Wang"},{"issue":"2","key":"10.1016\/j.jval.2022.07.009_bib28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40273-019-00853-x","article-title":"How uncertain is the survival extrapolation? A study of the impact of different parametric survival models on extrapolated uncertainty about hazard functions, lifetime mean survival and cost effectiveness","volume":"38","author":"Kearns","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"10.1016\/j.jval.2022.07.009_bib29","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.jval.2021.05.009","article-title":"The extrapolation performance of survival models for data with a cure fraction: a simulation study","volume":"24","author":"Kearns","year":"2021","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2022.07.009_bib30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40273-019-00867-5","article-title":"A\u00a0case study examining the usefulness of cure modelling for the prediction of survival based on data maturity","volume":"38","author":"Grant","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.jval.2022.07.009_bib31","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.jval.2020.02.015","article-title":"Bias in mean survival from fitting cure models with limited follow-up","volume":"23","author":"Othus","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2022.07.009_bib32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2407-5-48","article-title":"Minimum follow-up time required for the estimation of statistical cure of cancer patients: verification using data from 42 cancer sites in the SEER database","volume":"5","author":"Tai","year":"2005","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jval.2022.07.009_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12874-021-01460-1","article-title":"Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study","volume":"21","author":"Kearns","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jval.2022.07.009_bib34","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.ehrm.2012.01.001","article-title":"The ends justify the mean: outcome measures for estimating the value of new cancer therapies","volume":"3","author":"Davies","year":"2012","journal-title":"Health Outcomes Res Med"},{"issue":"9318","key":"10.1016\/j.jval.2022.07.009_bib35","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","article-title":"Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls","volume":"359","author":"Pocock","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jval.2022.07.009_bib36","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/ije\/dyy013","article-title":"Data maturity and follow-up in time-to-event analyses","volume":"47","author":"Gebski","year":"2018","journal-title":"Int J Epidemiol"},{"issue":"2","key":"10.1016\/j.jval.2022.07.009_bib37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1467-985X.2008.00573.x","article-title":"Accounting for uncertainty in health economic decision models by using model averaging","volume":"172","author":"Jackson","year":"2009","journal-title":"J\u00a0R Stat Soc Ser A Stat Soc"},{"issue":"Suppl 2","key":"10.1016\/j.jval.2022.07.009_bib38","doi-asserted-by":"crossref","first-page":"S402","DOI":"10.1016\/j.jval.2020.08.027","article-title":"Structural uncertainty in survival extrapolation: exploring the impact of four model averaging methods and adjusting for data maturity","volume":"23","author":"Hardern","year":"2020","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2022.07.009_bib39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/jrsm.1253","article-title":"Bayesian one-step IPD network meta-analysis of time-to-event data using Royston-Parmar models","volume":"8","author":"Freeman","year":"2017","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jval.2022.07.009_bib40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1471-2288-13-146","article-title":"Adjusting for measurement error in baseline prognostic biomarkers included in a time-to-event analysis: a joint modelling approach","volume":"13","author":"Crowther","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"10.1016\/j.jval.2022.07.009_bib41","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/0272989X19873661","article-title":"Generalized linear models for flexible parametric modeling of the hazard function","volume":"39","author":"Kearns","year":"2019","journal-title":"Med Decis Making"},{"issue":"11","key":"10.1016\/j.jval.2022.07.009_bib42","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/sim.2366","article-title":"Bayesian evidence synthesis to extrapolate survival estimates in cost-effectiveness studies","volume":"25","author":"Demiris","year":"2006","journal-title":"Stat Med"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522021052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522021052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:31:38Z","timestamp":1761096698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522021052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1098301522021052"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.07.009","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}